Financials

News Discussions Technicals Forecast Seasonals

NWRN fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

NWRN does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company